Osteonecrosis of the Jaw and Multiple Myeloma

Testicular cancer survivor Brian Sluga shares how faith, journaling and new goals, like training for marathons, helped him live a better life after cancer.

Five phase 3 trials presented at ESMO 2026 showed new options in small cell lung, bladder, prostate, KRAS G12C lung and stomach cancers. Here is what each found and what it means for patients.

An expert discusses infection risks after treatment, what follow-up care looks like and why patients with a rare cancer should ask questions, seek expert opinions and find community.

Median survival, hazard ratio, progression-free survival: a plain-language guide to the terms in cancer trial news, so you can tell what a result means for you and what to ask your care team.

Dr. Robert J. Kreitman explains how an experimental CAR T-cell therapy may help patients with relapsed hairy cell leukemia achieve lasting remissions.

Dr. Jacqueline Barrientos discussed how collaboration, individualized treatment and patient advocacy helped a 72-year-old man achieve leukemia remission and receive a kidney transplant.

Adding Imdelltra to Imfinzi maintenance helped people with extensive-stage small cell lung cancer live a median of 21.1 months vs. 12.7 months with Imfinzi alone in the phase 3 DeLLphi-305 trial.

The FDA approved Talzenna plus Xtandi for adults with HRR-mutated metastatic prostate cancer that has not been treated with, or is still responding to, androgen pathway drugs.